RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its
subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and
Distribution Agreement with an existing European partner for a new product that
will be marketed by its' Hospital Products Division. The new product utilizes a
patented delivery system that offers technical advantages over existing
alternatives and will be used in hospitals and acute care settings. These
products will provide hospitals, clinics, and healthcare professionals with
improved patient safety as well as operational efficiencies. The product will be
launched after Health Canada approval. 


"This is the third product that we have in-licensed from the same partner that
uses the same underlying patented technology. The first of the three is already
approved and being prepared for launch later this year or early next, and the
second is in the latter stages of the Health Canada approval process," said Rene
Goehrum, President and CEO of BioSyent. "We have already started discussions and
due diligence with our European partner on the fourth product that utilizes this
technology and we are aware that they are developing more such products. This
new product deal brings the combined number of products that BioSyent Pharma has
either in-market, Health Canada approved, or in-licensed to eight." 


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,801,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024